Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
Surgery|November 8, 2003
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) eraPeter C Wu, Alex Langerman, Christopher W Ryan, et al.
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.
Cancer|July 20, 2007
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancerR Bruce Montgomery, Peter S Nelson, Daniel Lin, et al.
Cancer Chemotherapy and Pharmacology|July 12, 2002
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancerChristopher W Ryan, Everett E Vokes, Nicholas J Vogelzang, et al.
American Journal of Clinical Oncology|February 3, 2005
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancerSupriya Gupta, Ann M Mauer, Christopher W Ryan, et al.
Urology|July 28, 2007
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapyChristopher W Ryan, Dezheng Huo, James W Stallings, et al.
Seminars in Oncology|April 12, 2017
What constitutes an "unmet medical need" in oncology? An empirical evaluation of author usage in the biomedical literatureEric Lu, Joseph Shatzel, Florence Shin, et al.
Oncology Nursing Forum|July 7, 2015
Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate CancerKerri M Winters-Stone, Nathan Dieckmann, Gianni F Maddalozzo, et al.
Cancer|July 14, 2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasMargaret von Mehren, Cathryn Rankin, John R Goldblum, et al.
Clinical Genitourinary Cancer|May 27, 2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapyTomasz M Beer, Bryan Goldman, Craig R Nichols, et al.
Pageof 15